CY1124648T1 - Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου - Google Patents

Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου

Info

Publication number
CY1124648T1
CY1124648T1 CY20211100512T CY211100512T CY1124648T1 CY 1124648 T1 CY1124648 T1 CY 1124648T1 CY 20211100512 T CY20211100512 T CY 20211100512T CY 211100512 T CY211100512 T CY 211100512T CY 1124648 T1 CY1124648 T1 CY 1124648T1
Authority
CY
Cyprus
Prior art keywords
bcl
antibody
inhibitor
combination
hodgkin
Prior art date
Application number
CY20211100512T
Other languages
English (en)
Inventor
Jan Endell
Konstantin PETROPOULOS
Peter Kelemen
Rainer Boxhammer
Markus Rückert
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CY1124648T1 publication Critical patent/CY1124648T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Η παρούσα αποκάλυψη περιγράφει έναν φαρμακευτικό συνδυασμό ενός αντισώματος αντι-CD19 και ενός αναστολέα BCL-2 για την θεραπεία μη Hodgkin λεμφώματος, χρόνιας λεμφοκυτταρικής λευχαιμίας και / ή οξείας λεμφοβλαστικής λευχαιμίας.
CY20211100512T 2016-10-28 2021-06-10 Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου CY1124648T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
CY1124648T1 true CY1124648T1 (el) 2022-07-22

Family

ID=57218739

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100512T CY1124648T1 (el) 2016-10-28 2021-06-10 Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου

Country Status (24)

Country Link
US (1) US20190241656A1 (el)
EP (2) EP3532098B1 (el)
JP (2) JP7094950B2 (el)
KR (2) KR102500868B1 (el)
CN (2) CN109890418B (el)
AU (1) AU2017348624B2 (el)
BR (1) BR112019008244A2 (el)
CA (1) CA3037246A1 (el)
CY (1) CY1124648T1 (el)
DK (1) DK3532098T3 (el)
ES (1) ES2871574T3 (el)
HR (1) HRP20210838T1 (el)
HU (1) HUE054496T2 (el)
IL (2) IL266216B2 (el)
LT (1) LT3532098T (el)
MX (2) MX2019004942A (el)
PL (1) PL3532098T3 (el)
PT (1) PT3532098T (el)
RS (1) RS62036B1 (el)
RU (1) RU2756405C2 (el)
SG (1) SG10202104036QA (el)
SI (1) SI3532098T1 (el)
WO (1) WO2018078123A1 (el)
ZA (1) ZA201903302B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018276384A1 (en) * 2017-05-31 2019-11-07 Incyte Corporation Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CN112638392B (zh) * 2018-08-31 2024-09-10 Adc治疗有限公司 组合疗法
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CA2534639C (en) 2003-07-31 2013-07-30 Immunomedics, Inc. Anti-cd19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP2270050B1 (en) 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
LT2211904T (lt) 2007-10-19 2016-11-25 Seattle Genetics, Inc. Cd19 surišantys agentai ir jų panaudojimas
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010151341A1 (en) 2009-06-24 2010-12-29 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20200058583A (ko) * 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
HUE058855T2 (hu) * 2011-08-16 2022-09-28 Morphosys Ag Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával
EP3476392A1 (en) * 2014-02-28 2019-05-01 Merck Sharp & Dohme Corp. Method for treating cancer
CA2972827A1 (en) 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine

Also Published As

Publication number Publication date
IL301786A (en) 2023-05-01
MX2019004942A (es) 2019-08-12
CN109890418B (zh) 2024-03-08
IL266216B1 (en) 2023-05-01
RU2019113370A3 (el) 2021-03-01
BR112019008244A2 (pt) 2019-07-16
JP7094950B2 (ja) 2022-07-04
RU2756405C2 (ru) 2021-09-30
DK3532098T3 (da) 2021-05-25
PT3532098T (pt) 2021-06-17
US20190241656A1 (en) 2019-08-08
SG10202104036QA (en) 2021-05-28
IL266216B2 (en) 2023-09-01
CN109890418A (zh) 2019-06-14
EP3532098A1 (en) 2019-09-04
ES2871574T3 (es) 2021-10-29
IL266216A (en) 2019-06-30
KR20190075942A (ko) 2019-07-01
EP3532098B1 (en) 2021-04-07
KR20230028571A (ko) 2023-02-28
RU2019113370A (ru) 2020-11-30
JP2019533682A (ja) 2019-11-21
HUE054496T2 (hu) 2021-09-28
EP3903821A1 (en) 2021-11-03
CA3037246A1 (en) 2018-05-03
JP2022137089A (ja) 2022-09-21
CN118045175A (zh) 2024-05-17
RS62036B1 (sr) 2021-07-30
WO2018078123A1 (en) 2018-05-03
HRP20210838T1 (hr) 2021-08-06
PL3532098T3 (pl) 2022-01-31
SI3532098T1 (sl) 2021-12-31
KR102500868B1 (ko) 2023-02-16
ZA201903302B (en) 2021-04-28
AU2017348624A1 (en) 2019-03-28
MX2022016270A (es) 2023-02-15
LT3532098T (lt) 2021-06-25
AU2017348624B2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
CY1124648T1 (el) Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου
CY1122653T1 (el) Αντισωματα αντι-τιgιτ, αντισωματα αντι-ρvrig και συνδυασμοι εξ αυτων
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
CY1125011T1 (el) Ενεργοποιουμενα αντισωματα enanti-cd71 και μεθοδοι χρησης αυτων
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112018067962A2 (pt) artigos absorventes
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CY1124706T1 (el) Συνδυασμοι και χρησεις αυτων
EP4360646A3 (en) Anti-tigit antibodies and methods of use
BR112017007170A2 (pt) anticorpos anti-ox40 humanizados e suas utilizações
MX2024000300A (es) Anticuerpos antitau y metodos de uso.
BR112018067525A2 (pt) anticorpos tendo especificidade para o btla e seus usos
WO2016062722A8 (en) Combination
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2021007274A (es) Molecula bifuncional anti-pd-1/sirpa.
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
PE20201272A1 (es) Actuador lineal accionado por correa de alta reduccion
CL2018003838S1 (es) Botella.
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
UY38352A (es) Inhibidores de integrina alfavbeta6